Multidrug-resistant (MDR) bacterial infections frequently arise in hostile tissue microenvironments—acidic pH, hypoxia, oxidative stress, and biofilm architecture—that blunt antibiotic activity and drive clinical failure. While isolated attempts to restore individual microenvironmental factors, such as pH or oxygenation, have shown promise, they rarely address the full spectrum of physicochemical disruptions at infection sites. This perspective proposes a modular, ultrasound-responsive microbubble (MB) platform that transiently reconditions infected niches in situ and thereby may augment standard antibiotics. Each MB population carries a single restorative cargo (for example, a pH buffer, an oxygen donor, or a redox modulator) and is designed for on-demand, spatially confined release via focused ultrasound (FUS); antibody functionalization can be added when needed to enhance site specificity. By selectively reprogramming multiple aspects of the infectious microenvironment, this approach aims to improve the performance of subsequent or concomitant antibiotic therapy, and even modest local gains may be clinically meaningful in critically ill patients with MDR infections. Preclinical work in oncology and infectious disease has reported that ultrasound-targeted microbubble destruction (UTMD) can remodel tissue architecture, enhance perfusion and oxygenation, disperse biofilms, and improve drug penetration. Integrating advances in microbubble engineering, ultrasound-triggered release, and microenvironment modulation, this perspective synthesizes the current evidence, outlines a translation-oriented workflow, and proposes a development roadmap that includes dosing screens under infection-mimicking conditions, infection-site imaging and safety studies using contrast-enhanced ultrasound (CEUS), and first-in-human feasibility in difficult biofilm infections.
Maxwel Adriano Abegg (Wed,) studied this question.